NCT03263637 - Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 24, 2017

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions

Relapsed or Refractory Haematological Malignancies IncludingAcute Myeloid LeukemiaAcute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaHigh Risk Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaRichter's SyndromeB-cell Non-Hodgkin LymphomaT-cell Non-Hodgkin LymphomaSmall Lymphocytic LymphomaMultiple Myeloma

Interventions

DRUG

AZD4573

AZD4573 will be administered as a intravenous (IV) infusion.

Trial Locations (12)

37075

Research Site, Göttingen

52074

Research Site, Aachen

53127

Research Site, Bonn

69120

Research Site, Heidelberg

89081

Research Site, Ulm

1105 AZ

Research Site, Amsterdam

3435 CM

Research Site, Nieuwegein

CF14 4XW

Research Site, Cardiff

M20 4BX

Research Site, Manchester

PL6 8DH

Research Site, Plymouth

S016 6YD

Research Site, Southampton

SM2 5PT

Research Site, Sutton